Equipment and technology
Top centres are equipped with bronchoscopy, interventional pulmonology, ECMO and advanced pulmonary-function and imaging platforms; infrastructure is broadly comparable with international standards.

Explore hospitals in our directory that appear in Fudan University’s 2023 top-ten specialty rankings related to this health area. Each card identifies the specialty and position that connects the hospital to this category.
If you are researching respiratory care in China or respiratory treatment in China for yourself or a family member, the practical question is simple: how does care here compare with the best centres abroad? Below is a grounded, numbers-based comparison written for international patients.
China’s leading respiratory centre — the First Affiliated Hospital of Guangzhou Medical University (Guangzhou Institute of Respiratory Health, ranked #1 in Fudan respiratory for 15 consecutive years, associated with Zhong Nanshan) — sits in the country’s first tier, with other strong centres such as China-Japan Friendship Hospital and PUMCH. As an international benchmark, National Jewish Health (ranked #1 respiratory hospital in the US by U.S. News) remains the global reference for respiratory care.
Top centres are equipped with bronchoscopy, interventional pulmonology, ECMO and advanced pulmonary-function and imaging platforms; infrastructure is broadly comparable with international standards.
China carries among the world’s largest burdens of chronic respiratory disease, COPD and lung cancer, so treatment volumes at major centres are very large. COPD management, lung-cancer multidisciplinary care and interventional pulmonology are standard at the top centres. Relative gaps remain in the very newest pulmonary therapies and in clinical-trial infrastructure versus National Jewish Health and similar institutions.
Standard respiratory medications — inhalers, biologics for asthma/COPD, and lung-cancer targeted/immunotherapy — are widely available; the newest agents can reach China later than the US/EU — verify per drug.
China has a large respiratory workforce with many clinicians trained internationally; research output is growing. International leaders still set more original research and guidelines, but the gap is narrowing.
| Metric | China | Global benchmark | Read |
|---|---|---|---|
| Chronic respiratory disease burden | Among the world’s largest (COPD, lung cancer) | US also high | Large scale, strong centres |
| Lung cancer | Leading cancer in China by incidence/mortality | US lung cancer declining | Major national focus |
China has among the world’s largest burdens of chronic respiratory disease (China CDC Weekly); lung cancer is a leading cancer in China.
Respiratory and lung-cancer care in China typically cost a fraction of US/EU prices — a core reason international patients consider lung cancer treatment in China.
At most top centres, waits for consultation and common procedures are shorter than in many public systems; international patient departments usually offer expedited booking.
Major centres run international clinics with English-speaking coordinators and self-pay / commercial insurance handling — directly relevant if you are weighing best hospitals for lung cancer in China.
Yes. Major respiratory centres regularly treat international patients, and many have dedicated international departments. Suitability is decided case by case by the treating team.
Yes. American patients commonly travel to China for planned lung-cancer evaluation or treatment, often for lower cost and shorter waits. Bring your scans and records, and allow time for translation and coordination.
The largest tertiary centres and their international departments provide English-speaking doctors and coordinators. For other settings, a medical interpreter or coordinator such as Wellward China is recommended.
Through a hospital international clinic, a local coordinator, or by contacting a service like Wellward China with your records and goals. Appointments at top centres can often be arranged faster than in many public systems.
A comparable treatment course is typically a fraction of US prices in China, largely because of lower hospital and staffing costs and widely available generics. Exact figures vary by stage, drug regimen and whether radiotherapy/surgery is used — request a written quote per case.
US prices reflect hospital charges, specialist fees, insurance administration and high drug costs. That gap is exactly why some international patients explore cancer treatment cost in China vs USA as a pragmatic alternative.
For common, high-prevalence respiratory needs — COPD, asthma, lung-cancer care — China’s top centres are highly competitive on cost, access and quality. For the very newest pulmonary or oncologic therapies, China can be an efficient, pragmatic option, ideally combined with an international second opinion.
This category covers breathing and lung concerns. Respiratory Medicine and Thoracic Surgery form the primary links; tuberculosis and allergy-related specialties are supplementary for specific situations. The Chinese labels below follow the names shown in the Fudan specialty rankings.
Main association for lung and breathing conditions managed by respiratory specialists.
Main association for selected lung and chest conditions where surgical evaluation may be relevant.
May be relevant to suspected or diagnosed tuberculosis, rather than respiratory concerns generally.
May be relevant to selected allergic or immune-mediated airway conditions.
Cards merge hospitals that appear in more than one relevant specialty list. Each badge keeps its specialty and rank visible; none of the positions is a cross-specialty overall ranking.
The relevant specialty depends on the patient’s records, symptoms and goals. Browse the hospital directory or contact us to discuss practical information and coordination options.
Share your question, relevant records and intended travel timing. We can explain possible coordination steps.
Talk to a Concierge →